Christoph Gasche

Christoph Gasche

Auto-generated profile, based on publicly available information

Christoph Gasche

Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MSMark S Silverberg
Mark S Silverberg
JSJack Satsangi
Jack Satsangi
TATariq Ahmad
Tariq Ahmad
IAIan Dr Arnott
Ian Dr Arnott
CBCharles N Bernstein
Charles N Bernstein
BWBryan F Warren
Bryan F Warren
The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn’s disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.

1 February 2000 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
CGC Gasche
C Gasche
JSJ Scholmerich
J Scholmerich
JBJ Brynskov
J Brynskov
GDG D'Haens
G D'Haens
SHS B Hanauer
S B Hanauer
LSL R Sutherland
L R Sutherland
Summary. Crohn's disease is a heterogeneous entity. Previous attempts of classification have been based primarily on anatomic location and behavior of disease.

16 January 2015 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
ADAxel Dignass
Axel Dignass
CGChristopher Gasche
Christopher Gasche
DBDominik Bettenworth
Dominik Bettenworth
GBGunnar Birgegård
Gunnar Birgegård
SDSilvio Danese
Silvio Danese
SVStephan Vavricka
Stephan Vavricka

15 February 2006 in Gut
Verified
Journal Article
Open access
PDF file
ESEduard Stange
Eduard Stange
STS P L Travis
S P L Travis
SVSeverine Vermeire
Severine Vermeire
CBC Beglinger
C Beglinger
LKL Kupcinkas
L Kupcinkas
WRW Reinisch
W Reinisch
The consensus endeavours to address these differences. The consensus is not meant to supersede the guidelines of different countries (such as those from the UK,2 Germany,3 or France), which reach broadly the same conclusions as they are, after all, based on the same evidence. Rather, the aim of the consensus is to promote a European perspective on the management of CD and its dilemmas. As the development of guidelines is an expensive and time consuming process, it may help to avoid duplication of effort in the future. A consensus is also considered important because an increasing number of therapeutic trials are based in Europe, especially in eastern European countries where practice guidelines have yet to be published.

9 July 2004 in Gut
Verified
Journal Article
Open access
PDF file
CGC Gasche
C Gasche
MLMiranda C E Lomer
Miranda C E Lomer
ICI Cavill
I Cavill
GWGünter Weiss
Günter Weiss
Iron deficiency anaemia is one of the most common disorders in the world. Also, one third of inflammatory bowel disease (IBD) patients suffer from recurrent anaemia. Anaemia has significant impact on the quality of life of affected patients. Chronic fatigue, a frequent IBD symptom itself, is commonly caused by anaemia and may debilitate patients as much as abdominal pain or diarrhoea. Common therapeutic targets are the mechanisms behind anaemia of chronic disease and iron deficiency. It is our experience that virtually all patients with IBD associated anaemia can be successfully treated with a combination of iron sucrose and erythropoietin, which then may positively affect the misled immune response in IBD.

1 December 2007 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
CGChristoph Gasche
Christoph Gasche
ABArnold Berstad
Arnold Berstad
RBRagnar Befrits
Ragnar Befrits
CBChristoph Beglinger
Christoph Beglinger
ADAxel Dignass
Axel Dignass
GAGert Van Assche
Gert Van Assche